Equities Analysts Issue Forecasts for BrainsWay Q4 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – Equities researchers at Northland Capmk raised their Q4 2024 earnings estimates for BrainsWay in a report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.02 per share for the quarter, up from their previous estimate of $0.01. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities upped their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

BrainsWay Stock Performance

BWAY stock opened at $9.12 on Friday. The company has a market capitalization of $152.12 million, a P/E ratio of 91.21 and a beta of 1.25. BrainsWay has a 52-week low of $4.30 and a 52-week high of $10.98. The company has a fifty day moving average price of $9.23 and a 200-day moving average price of $7.46.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. During the same quarter in the previous year, the company posted ($0.01) EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Good Life Advisors LLC increased its holdings in BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares in the last quarter. Perritt Capital Management Inc bought a new position in shares of BrainsWay in the 2nd quarter worth $121,000. Acadian Asset Management LLC increased its position in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after purchasing an additional 84,371 shares during the last quarter. Rhumbline Advisers raised its position in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after purchasing an additional 1,695 shares during the period. Finally, Virtu Financial LLC purchased a new position in BrainsWay in the 1st quarter worth approximately $60,000. 30.11% of the stock is owned by institutional investors and hedge funds.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.